ASH is in full swing
STAT's Adam Feuerstein spent the weekend working at the annual meeting of the American Society of Hematology in Orlando. If you were offline or otherwise not paying attention, here’s your chance to catch up.
On Saturday, Adam wrote about BCMA-targeted immunotherapies for multiple myeloma, the impact that socioeconomic factors are affecting clinical trial outcomes and an update on a sickle cell gene therapy. Check out the highlights here.
Yesterday, his science-heavy dispatch covered the potential for a pill to cure sickle cell disease, a company turning stem cells into cancer killers and the marketing battle between two giant BTK blockers. That one is available right here.
On Saturday, Adam wrote about BCMA-targeted immunotherapies for multiple myeloma, the impact that socioeconomic factors are affecting clinical trial outcomes and an update on a sickle cell gene therapy. Check out the highlights here.
Yesterday, his science-heavy dispatch covered the potential for a pill to cure sickle cell disease, a company turning stem cells into cancer killers and the marketing battle between two giant BTK blockers. That one is available right here.
.png)
No hay comentarios:
Publicar un comentario